GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines
Phase 1
Completed
- Conditions
- Prophylaxis Herpes Simplex
- Interventions
- Biological: Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141Biological: Herpes simplex virus containing gD-Alum
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 130
- Registration Number
- NCT00698490
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Gent, Belgium
Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients
Phase 1
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL vaccine 208129Biological: Engerix™-B
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00699231
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Brussels, Belgium
Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects
Phase 3
Completed
- Conditions
- Prophylaxis for Herpes Simplex
- Interventions
- Biological: Herpes simplex candidate vaccine- adjuvanted GSK 208141Biological: Placebo
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7460
- Registration Number
- NCT00698568
- Locations
- 🇨🇭
GSK Clinical Trials Call Center, Basel, Switzerland
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y
Phase 2
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL vaccineBiological: Engerix™-B
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT00698906
- Locations
- 🇦🇹
GSK Clinical Trials Call Center, Wien, Austria
Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-BBiological: HBV-MPL vaccine 208129
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 230
- Registration Number
- NCT00697749
Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-BBiological: HBV-MPL vaccine 208129
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 145
- Registration Number
- NCT00698061
Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents
Phase 2
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL vaccine Formulation BBiological: Engerix™-BBiological: HBV-MPL vaccine Formulation A
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2008-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00697775
- Locations
- 🇩🇪
GSK Clinical Trials Call Center, Mainz, Germany
Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Recombinant MPL- adjuvanted hepatitis B vaccineBiological: Engerix™-B
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2008-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 116
- Registration Number
- NCT00697931
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Leuven, Belgium
Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL 208129Biological: Engerix™-BBiological: Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2008-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00697840
- Locations
- 🇦🇹
GSK Clinical Trials Call Center, Vienna, Austria
Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant
Phase 2
Completed
- Conditions
- Prophylaxis Herpes Simplex
- Interventions
- Biological: Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvantBiological: Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2008-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00697567
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Gent, Belgium
© Copyright 2025. All Rights Reserved by MedPath